Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Editas Medicine ( (EDIT) ) has issued an announcement.
On May 14, 2025, Editas Medicine announced new in vivo data showcasing the potential of their gene upregulation strategy in hematopoietic stem cells (HSCs) at the American Society of Gene and Cell Therapy Annual Meeting. The data demonstrated that a single dose of their proprietary targeted lipid nanoparticle (tLNP) achieved therapeutically relevant levels of HBG1/2 promoter editing in both humanized mice and non-human primates, exceeding the predicted therapeutic threshold. This approach, which targets HBG1/2 promoters to upregulate fetal hemoglobin, is in pre-clinical development for treating sickle cell disease and beta thalassemia, potentially positioning Editas Medicine as a leader in in vivo gene editing therapies.
The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.
Spark’s Take on EDIT Stock
According to Spark, TipRanks’ AI Analyst, EDIT is a Neutral.
Editas Medicine’s overall stock score reflects significant financial challenges, with persistent losses and no current revenue, leading to a speculative valuation. The company’s strong cash reserves provide some buffer, but the continuous negative cash flows highlight ongoing operational struggles. Technical indicators suggest short-term stability but caution for the long-term outlook. The recent positive corporate event regarding gene editing advancements offers some strategic promise, but the high-risk profile remains, making it suitable primarily for risk-tolerant investors.
To see Spark’s full report on EDIT stock, click here.
More about Editas Medicine
Editas Medicine is a pioneering gene editing company focused on leveraging the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems to develop a pipeline of in vivo medicines for serious diseases globally. The company aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines and holds exclusive licenses for the Cas12a and Cas9 patent estates from the Broad Institute and Harvard University.
Average Trading Volume: 3,725,194
Technical Sentiment Signal: Sell
Current Market Cap: $128.9M
See more insights into EDIT stock on TipRanks’ Stock Analysis page.